Foghorn Therapeutics Company Insiders
| FHTX Stock | USD 7.84 0.12 1.55% |
Foghorn Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Foghorn Therapeutics suggests that vertually all insiders are panicking. Foghorn Therapeutics employs about 116 people. The company is managed by 17 executives with a total tenure of roughly 271 years, averaging almost 15.0 years of service per executive, having 6.82 employees per reported executive.
Foghorn Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-09-23 | Carlos Costa | Disposed 857 @ 10.17 | View | ||
| 2024-09-20 | Carlos Costa | Disposed 35756 @ 10.04 | View |
Monitoring Foghorn Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Foghorn |
Foghorn Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2045) % which means that it has lost $0.2045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7038) %, meaning that it created substantial loss on money invested by shareholders. Foghorn Therapeutics' management efficiency ratios could be used to measure how well Foghorn Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.34 in 2024, whereas Return On Tangible Assets are likely to drop (0.36) in 2024. At this time, Foghorn Therapeutics' Fixed Asset Turnover is fairly stable compared to the past year. Asset Turnover is likely to rise to 0.13 in 2024, whereas Total Assets are likely to drop slightly above 280.8 M in 2024.Common Stock Shares Outstanding is likely to drop to about 39.2 M in 2024. Net Loss is likely to drop to about (102.9 M) in 2024
Foghorn Therapeutics Workforce Comparison
Foghorn Therapeutics is rated # 3 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 615. Foghorn Therapeutics retains roughly 116 in number of employees claiming about 19% of equities under Health Care industry.
Foghorn Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Foghorn Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Foghorn Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Foghorn Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 0.5455 | 6 | 11 | 248,859 | 137,718 |
| 2024-03-01 | 6.0 | 6 | 1 | 740,000 | 11,000 |
| 2023-09-01 | 1.0 | 3 | 3 | 646,297 | 685,594 |
| 2023-06-01 | 9.0 | 9 | 1 | 428,000 | 300,000 |
| 2023-03-01 | 4.5 | 9 | 2 | 939,310 | 189,310 |
| 2022-12-01 | 2.0 | 2 | 1 | 36,371 | 4,371 |
| 2022-09-01 | 0.2308 | 3 | 13 | 164,000 | 655,614 |
| 2022-06-01 | 12.0 | 12 | 1 | 192,000 | 675.00 |
| 2022-03-01 | 0.2941 | 5 | 17 | 985,000 | 748,647 |
| 2021-12-01 | 0.3333 | 1 | 3 | 104,310 | 437,643 |
| 2021-09-01 | 9.0 | 9 | 1 | 151,964 | 23,000 |
| 2021-06-01 | 0.6667 | 2 | 3 | 37,590 | 24,324 |
| 2020-12-01 | 0.4483 | 13 | 29 | 14,098,088 | 24,809,377 |
Foghorn Therapeutics Notable Stakeholders
A Foghorn Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Foghorn Therapeutics often face trade-offs trying to please all of them. Foghorn Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Foghorn Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Adrian Gottschalk | CEO President | Profile | |
| Stephen DiPalma | Treasurer CFO | Profile | |
| Karin Hellsvik | Corporate VP | Profile | |
| Michael GarciaWebb | VP Research | Profile | |
| Saurabh Sewak | Vice Development | Profile | |
| Kristian MBA | Chief Officer | Profile | |
| Allan MD | Chief Officer | Profile | |
| Alfonso MD | Chief Officer | Profile | |
| Gerald Md | Founder Board | Profile | |
| Fanny Cavalie | Chief Officer | Profile | |
| Carlos Costa | Chief Officer | Profile | |
| Michael JD | Chief Officer | Profile | |
| Ben Strain | VP Communications | Profile | |
| Michael LaCascia | Chief Officer | Profile | |
| Anna Rivkin | Chief Officer | Profile | |
| Steven Bellon | Chief Officer | Profile | |
| MPH MD | Chief Officer | Profile |
About Foghorn Therapeutics Management Performance
The success or failure of an entity such as Foghorn Therapeutics often depends on how effective the management is. Foghorn Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Foghorn management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Foghorn management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.47) | (0.50) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | 1.28 | 1.34 |
Please note, the imprecision that can be found in Foghorn Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Foghorn Therapeutics. Check Foghorn Therapeutics' Beneish M Score to see the likelihood of Foghorn Therapeutics' management manipulating its earnings.
Foghorn Therapeutics Workforce Analysis
Traditionally, organizations such as Foghorn Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Foghorn Therapeutics within its industry.Foghorn Therapeutics Manpower Efficiency
Return on Foghorn Therapeutics Manpower
| Revenue Per Employee | 294.4K | |
| Revenue Per Executive | 2M | |
| Net Loss Per Employee | 848.5K | |
| Net Loss Per Executive | 5.8M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 10.7M |
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.